- Clifford J. Stocks - Chief Executive Officer
Clifford J. Stocks
Chief Executive Officer
Mr. Stocks brings more than twenty-five years of experience in the biotech industry to OncoResponse. Most recently, Mr. Stocks served as Chief Executive Officer at Theraclone Sciences, where he was responsible for leading all aspects of the company’s efforts to discover and develop novel therapeutic antibody immunotherapies for the treatment of infectious disease. Prior to Theraclone, Mr. Stocks served as Chief Business Officer of Calistoga Pharmaceuticals, Inc., where he led the partnering activities and M&A teamwork that resulted in the acquisition of Calistoga by Gilead for $600 million in Q2 2011. Prior to Calistoga, Mr. Stocks spent over 15 years at ICOS Corporation, where he served as an Executive Officer and Vice President of Business Development. While at ICOS, he led acquisitions and joint venture activities, as well as alliance formation, strategy, licensing and deal making. He played an instrumental role on the leadership team that developed and launched Cialis®, and was a key architect of the Lilly ICOS joint venture partnership leading to the $2.3 billion acquisition of ICOS in 2007. Mr. Stocks's early career includes a turn as a management consultant in the Health Services practice of Booz, Allen & Hamilton, as well as academic research in the department of immunology at the University of Utah and the department of molecular genetics and cell biology at the University of Chicago.
Mr. Stocks received a Master of Business Administration degree from the University of Chicago, Booth Graduate School of Business and a Bachelor of Science degree in biology from the University of Utah.
- Kristine Swiderek, Ph.D. - Chief Scientific Officer
Kristine Swiderek, Ph.D.
Chief Scientific Officer
Dr. Swiderek has over 18 years of research and leadership experience in the biopharmaceutical industry and a proven track record of discovering and developing a wide variety of protein therapeutics. Most recently, Dr. Swiderek was Chief Scientific Officer of Theraclone Sciences, where she led development of the I-STARTM antibody discovery platform. Prior to Theraclone, Dr. Swiderek served as Vice President of Protein Science at ZymoG enetics, a Seattle -based public biotechnology company specializing in development of protein therapeutics, where she successfully built a world-class protein science department that advanced over a dozen therapeutic molecule candidates to be partnered, out-licensed and into clinical development. Prior to ZymoGenetics, Dr. Swiderek established a state-of-the-art analytical core facility at the City of Hope, National Cancer Center where she collaborated with a group of prestigious scientists. She has authored and co-authored over 60 peer reviewed articles and book chapters and has been a guest speaker at international scientific meetings and conventions.
Dr. Swiderek holds a Ph.D. in Protein Biochemistry from the Ruhr-Universität in Bochum, Germany. She completed her post- doctoral studies at City of Hope, Beckman Research Institute, in Duarte, California and the Department of Biochemistry and Molecular Biology at Indiana University, Indianapolis, Indiana.
- Russ Hawkinson - Chief Financial Officer
Chief Financial Officer
Mr. Hawkinson is an experienced financial executive with over 17 years of experience in the life sciences industry. Most recently, Mr. Hawkinson served as Chief Financial Officer of Theraclone Sciences, where he led all areas of finance, strategy, and corporate development. Prior to Theraclone, Mr. Hawkinson was Vice President, Finance and Accounting at CTI Biopharma, where he was responsible for SEC reporting, Treasury, and finance functions. Previously, Mr. Hawkinson was Vice President, Finance at Corixa Corporation, where he directed the finance and accounting functions, including all aspects of planning and reporting, operational accounting, and oversight of all SEC-related activities. Prior to Corixa, Mr. Hawkinson was an audit senior manager at Ernst & Young.
Mr. Hawkinson earned his B.A. from the University of Washington and received his CPA in Washington State.